// OVERVIEW
Global pharmaceutical company with major franchises in diabetes, oncology, and immunology.
Discussed in
- AI's M&A watchlist
- Axios Pro Rata_ California clanger — 2026-09-01
- 50 VCs that actually delivered
- 🔥Record Investments, Slowing Economy - Here's the State of the Market in August 2026
- Decacorns are the new unicorns
- 💡 Army of agents
- Biotech IPOs get their groove back
- SpaceX builds a lockup ladder
- OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze
- Microsoft sets OpenAI free
- Axios Pro Rata_ Kushner plays ball
- Eli Lilly's $7B hedge against GLP-1s
// RECENT MENTIONS
// SIGNALS
24 SIGNALS
01
m_and_a·PitchBook News·SEPTEMBER 1, 2026
“Eli Lilly & Co. agreed to acquire Bain Capital Life Sciences-backed Merida Biosciences, a biotech company developing drugs for autoimmune and allergic diseases, in a $2.88 billion deal.”
Source→02
m_and_a·Axios Pro Rata·SEPTEMBER 1, 2026
“Eli Lilly agreed to acquire Merida Biosciences…for up to $2.88b in cash.”
Source→03
funding·PitchBook News·AUGUST 19, 2026
AI-extracted from podcast / newsletter / paper summaries. May contain errors.